<\/p>\n
How an Australian Placebo-Controlled Study Demonstrated 34% Pain Reduction with Audio Frequency Therapy – And What This Means for Modern Frequency Devices<\/em><\/p>\n In the world of alternative health, skeptics often ask: “Where is the scientific evidence?”<\/strong><\/p>\n For frequency therapy, one answer lies in Australia, 1993. A rigorous placebo-controlled clinical trial<\/strong> – the gold standard in medical research – showed significant benefits for arthritis patients who used Rife-like audio frequency technology. <\/p>\n This was not a testimonial. This was not anecdotal evidence. This was 49 volunteers, three months of treatment, controlled conditions, and blood tests<\/strong> – all under scientific supervision. <\/p>\n The results? Convincing enough to obtain TGA (Therapeutic Goods Administration) registration<\/strong> in Australia – official government approval that the device delivers what it promises. <\/p>\n Let’s dive into what this groundbreaking study discovered, and why it is still relevant today for anyone interested in frequency therapy.<\/p>\n The study was conducted from May 10 to Aug. 14, 1993,<\/strong> at the Tuggerah Lakes Community Centre on the Central Coast of New South Wales, Australia.<\/p>\n The research was initiated by BWBGELTECH PTY LTD<\/strong>, led by Geoff Baker (B. App. Sci)<\/strong>, Director of Research & Development. Baker had devoted years of his life and considerable resources to studying and perfecting his PET (Pulsed Electro-Therapy) device. <\/p>\n The study included collaboration with:<\/p>\n The study recruited 49 randomly selected volunteers<\/strong> on those members: <\/p>\n All participants experienced prolonged, persistent joint pain and inflammation – not mild or temporary symptoms.<\/p>\n The study used 34 Audio Frequency Therapy Units (AFTUs)<\/strong> – pocket-sized, computerized devices that applied specific frequency programs via contact electrodes. This device later became the PET<\/strong> unit, which eventually achieved TGA registration (ARTG No. AUST L 48725) for arthritic therapy in Australia. <\/p>\n What makes this study particularly valuable is its rigorous methodology.<\/p>\n The study used what scientists consider the gold standard<\/strong> for clinical trials: <\/p>\n This design eliminates both the placebo effect<\/strong> (patients improve because they believe they are being treated) and investigator bias<\/strong> (practitioners unknowingly favoring certain patients).<\/p>\n???? Table of contents<\/h2>\n
\n
????\ufe0f Study Background: Who, What, When<\/h2>\n
The Organization Behind<\/h3>\n
\n
The Participants<\/h3>\n
\n
The Device<\/h3>\n
???? The Methodology: Why This Study Is Important<\/h2>\n
Double-blind, Placebo-Controlled Design.<\/h3>\n
\n
Treatment protocol<\/h3>\n